ConvergencePublished by Wavelens
ENESPT
Log inCreate account
Life Sciences · Archive · 3 editions

Longevity & Human Performance

← All industries

Radar, quarter by quarter

ForceQ1 2026Q2 2026Q3 2026
AI45▲ +14▼ -1
Energy111
Quantum222
Robotics32▼ -12
Health Evo555
Q3 2026Current edition

Aging got a price tag and a meter.

In Q3 2026, aging got a price and a meter. Medicare started paying for GLP-1s at a $50 copay and enrolled 600,000 seniors in two months, while Neko Health and Function Health raised $1.15 billion to measure the body and a Phase 2a trial used six proteomic clocks to read biological age as an endpoint. The money went to measuring and distributing healthspan; rejuvenation therapeutics produced no clinical readout inside the quarter.

Health Evo5/5
AI4/5
Quantum2/5
Robotics2/5
Energy1/5
WhyMembersWhatMembersHowMembers
Q2 2026

The needle disappears. The machine proves itself.

In Q2 2026, GLP-1 lost its needle: Lilly's Foundayo became the first oral GLP-1 pill for weight loss, FDA-approved April 1, with 80% of early patients previously unwilling to self-inject. In the same quarter, Isomorphic Labs raised $2.1 billion · the largest private AI drug discovery round in history · and NewLimit secured $435 million from Founders Fund and Lilly Ventures to bring epigenetic reprogramming into human clinical trials. Three pivots, one quarter.

AI5/5
Health Evo5/5
Quantum2/5
Robotics2/5
Energy1/5
WhyMembersWhatMembersHowMembers
Q1 2026

The biology- to-clinic inflection

In Q1 2026, the FDA cleared the first human trial of an epigenetic reprogramming therapy · a line that separates longevity from theory. Meanwhile, Eli Lilly's GLP-1 revenues reached $8.66 billion in a single quarter, and longevity biotech raised $3.74 billion, 56% above Q1 2025. The biology-to-clinic pipeline is no longer a roadmap: it is a schedule.

Health Evo5/5
AI4/5
Robotics3/5
Quantum2/5
Energy1/5
WhyMembersWhatMembersHowMembers